Sadia Saleem
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sadia Saleem as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:15 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06966050 · Multi-center MRD Registry for Inflammatory Breast CancerM.D. Anderson Cancer Center · recruiting · Breast Cancer · principal investigator
- Ph1/Ph2NCT05041101 · Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast CancerM.D. Anderson Cancer Center · terminated · Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:15 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.Invest New Drugs · 202122 citationsRCR 1.1
- Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.Cancer Res Commun · 202412 citationsRCR 1.6
- 6 citationsRCR 0.5